search
Back to results

Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis

Primary Purpose

Osteoarthritis of the Knee

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
PENNSAID Gel
Vehicle
Sponsored by
Mallinckrodt
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis of the Knee focused on measuring Osteoarthritis, Arthritis, NSAIDs, Topical NSAID, Diclofenac, PENNSAID

Eligibility Criteria

40 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Primary osteoarthritis of the knee
  2. Radiologic evidence of OA of the knee
  3. On stable pain therapy with an oral or topical NSAID or acetaminophen
  4. Experience a "moderate flare" of pain following washout of stable pain therapy
  5. Able to read and understand English or Spanish to answer pain assessment questions without any explanation
  6. If female, surgically sterile or non-pregnant
  7. Except for OA, in reasonably good general health
  8. Written informed consent

Exclusion Criteria:

  1. Secondary OA of the study knee
  2. History of pseudo gout or inflammatory flare-ups
  3. Participation would conflict with contraindications, warnings or precautions as stated in the prescribing information for oral or topical diclofenac
  4. Severe, uncontrolled cardiac, renal, hepatic, or other systemic disease
  5. Any malignancy within the previous 3 years, except local therapy for superficial skin cancer not on the study knee
  6. Known sensitivity to the use of oral or topical diclofenac, aspirin [acetylsalicylic acid (ASA)] or any other NSAID, dimethyl sulfoxide (DMSO), or ethanol
  7. Ongoing abnormality that could confound interpretation of the safety results (eg, anemia, unresponsive gastrointestinal [GI] reflux, etc.)
  8. Documented gastroduodenal ulcer or any GI bleeding (except hemorrhoidal) within the last 6 months
  9. Uncontrolled diabetes
  10. Screening laboratory test results of serum creatinine ≥ 1.5 times upper limit of normal; aspartate aminotransferase (AST), alanine aminotransferase (ALT), or gamma-glutamyltransferase (GGT) ≥ 3 times upper limit of normal; and hemoglobin less than or equal to lower limit of normal
  11. Documented alcohol or drug abuse within 1 year
  12. If female, breast-feeding
  13. Major surgery or previous damage to the study knee at any time, or minor knee surgery to the study knee within 1 year
  14. Requires oral or intra-muscular corticosteroids, or received an intra articular corticosteroid injection into the study knee within the past 90 days, or into any other joint within the past 30 days, or currently applying topical corticosteroids onto the study knee
  15. Received intra-articular viscosupplementation (eg, hylan G-F 20 [Synvisc®]) in the study knee in the past 6 months
  16. On prior stable therapy (ie, more than 3 days per week for the previous month) with an opioid analgesic prior to the screening visit will be excluded.
  17. Recently started taking a sedative hypnotic medication for insomnia
  18. Taking anti-depressants
  19. Not willing to discontinue prohibited medications/therapies
  20. Cannot tolerate acetaminophen
  21. Re-entering study after dropping out or withdrawn from study
  22. Used another investigational drug within the previous 30 days
  23. On or currently applying for disability benefits on the basis of knee OA
  24. History of fibromyalgia
  25. Other painful or disabling conditions affecting the knee or leg, or disabling condition of the hands (used to apply the study drug)
  26. Skin disorder with current involvement on the hands (used to apply the study drug) or the knee(s) (application site)
  27. Referred to an orthopedic surgeon for consideration of, or been advised to have, knee replacement or knee reconstruction surgery
  28. Radiologic evidence of OA of the knee advanced to the point that all cartilage has been eroded (ie, bone on bone)
  29. Recently started using a cane within the past 30 days
  30. History of chronic headaches that may require more than occasional use of rescue medication for headaches

Sites / Locations

  • Genova Clinical Research
  • Benchmark Research
  • Tampa Bay Medical Research, Inc
  • Avail Clinical Research
  • Comprehensive NeuroScience Inc.
  • Drug Studies America
  • South Coast Medical Group
  • Clinical Trials Technology, Inc.
  • Sterling Research
  • Radiant Research Inc.
  • Sundance Clinical Research
  • Clinical Study Center of Asheville
  • Peters Medical Research, LLC
  • Crescent Medical Research
  • New Hanover Medical Research
  • Sterling Research
  • Radiant Research Inc.
  • Clinical Research Source, Inc.
  • Radiant Research Inc.
  • Palmetto Medical Research
  • Holston Medical Group Clinical Research
  • Benchmark Research
  • Benchmark Research
  • Sun Research Institute
  • Charlottesville Medical Research
  • HypotheTest, LLC

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

PENNSAID Gel

Vehicle

Arm Description

Diclofenac sodium 2.0% w/w

The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium

Outcomes

Primary Outcome Measures

Pain When Walking On A Flat Surface
Participants rate their pain intensity when walking on a flat surface as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Pain When Walking On A Flat Surface
Participants rate their pain intensity when walking on a flat surface as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Pain When Going Up Or Down Stairs
Participants rate their pain intensity when going up or down stairs as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Pain When Going Up Or Down Stairs
Participants rate their pain intensity when going up or down stairs as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Pain At Night While In Bed
Participants rate their pain intensity at night while in bed as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Pain At Night While In Bed
Participants rate their pain intensity at night while in bed as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Pain While Sitting Or Lying Down
Participants rate their pain intensity while sitting or lying down as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Pain While Sitting Or Lying Down
Participants rate their pain intensity while sitting or lying down as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Pain While Standing
Participants rate their pain intensity while standing as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Pain While Standing
Participants rate their pain intensity while standing as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.

Secondary Outcome Measures

Full Information

First Posted
April 28, 2010
Last Updated
October 18, 2019
Sponsor
Mallinckrodt
search

1. Study Identification

Unique Protocol Identification Number
NCT01119898
Brief Title
Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis
Official Title
A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Clinical Study to Evaluate the Safety and Efficacy of PENNSAID Gel in the Symptomatic Treatment of Osteoarthritis of the Knee
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
August 2, 2010 (Actual)
Primary Completion Date
February 16, 2011 (Actual)
Study Completion Date
February 16, 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mallinckrodt

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Osteoarthritis (OA) is the most common form of arthritis. It can cause pain, swelling, and reduced motion in the joints. That can reduce quality of life. OA can occur in any joint, but usually affects the hands, knees, hips or spine. The purpose of this study is to find out if doctors might be able to use 2% PENNSAID gel to treat OA in the knee.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis of the Knee
Keywords
Osteoarthritis, Arthritis, NSAIDs, Topical NSAID, Diclofenac, PENNSAID

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
260 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PENNSAID Gel
Arm Type
Experimental
Arm Description
Diclofenac sodium 2.0% w/w
Arm Title
Vehicle
Arm Type
Placebo Comparator
Arm Description
The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
Intervention Type
Drug
Intervention Name(s)
PENNSAID Gel
Other Intervention Name(s)
diclofenac sodium 2.0% w/w
Intervention Description
2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
Intervention Type
Drug
Intervention Name(s)
Vehicle
Intervention Description
2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
Primary Outcome Measure Information:
Title
Pain When Walking On A Flat Surface
Description
Participants rate their pain intensity when walking on a flat surface as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Time Frame
at Baseline
Title
Pain When Walking On A Flat Surface
Description
Participants rate their pain intensity when walking on a flat surface as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Time Frame
at Week 4
Title
Pain When Going Up Or Down Stairs
Description
Participants rate their pain intensity when going up or down stairs as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Time Frame
at Baseline
Title
Pain When Going Up Or Down Stairs
Description
Participants rate their pain intensity when going up or down stairs as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Time Frame
at Week 4
Title
Pain At Night While In Bed
Description
Participants rate their pain intensity at night while in bed as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Time Frame
at Baseline
Title
Pain At Night While In Bed
Description
Participants rate their pain intensity at night while in bed as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Time Frame
at Week 4
Title
Pain While Sitting Or Lying Down
Description
Participants rate their pain intensity while sitting or lying down as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Time Frame
at Baseline
Title
Pain While Sitting Or Lying Down
Description
Participants rate their pain intensity while sitting or lying down as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Time Frame
at Week 4
Title
Pain While Standing
Description
Participants rate their pain intensity while standing as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Time Frame
at Baseline
Title
Pain While Standing
Description
Participants rate their pain intensity while standing as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.
Time Frame
at Week 4

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Primary osteoarthritis of the knee Radiologic evidence of OA of the knee On stable pain therapy with an oral or topical NSAID or acetaminophen Experience a "moderate flare" of pain following washout of stable pain therapy Able to read and understand English or Spanish to answer pain assessment questions without any explanation If female, surgically sterile or non-pregnant Except for OA, in reasonably good general health Written informed consent Exclusion Criteria: Secondary OA of the study knee History of pseudo gout or inflammatory flare-ups Participation would conflict with contraindications, warnings or precautions as stated in the prescribing information for oral or topical diclofenac Severe, uncontrolled cardiac, renal, hepatic, or other systemic disease Any malignancy within the previous 3 years, except local therapy for superficial skin cancer not on the study knee Known sensitivity to the use of oral or topical diclofenac, aspirin [acetylsalicylic acid (ASA)] or any other NSAID, dimethyl sulfoxide (DMSO), or ethanol Ongoing abnormality that could confound interpretation of the safety results (eg, anemia, unresponsive gastrointestinal [GI] reflux, etc.) Documented gastroduodenal ulcer or any GI bleeding (except hemorrhoidal) within the last 6 months Uncontrolled diabetes Screening laboratory test results of serum creatinine ≥ 1.5 times upper limit of normal; aspartate aminotransferase (AST), alanine aminotransferase (ALT), or gamma-glutamyltransferase (GGT) ≥ 3 times upper limit of normal; and hemoglobin less than or equal to lower limit of normal Documented alcohol or drug abuse within 1 year If female, breast-feeding Major surgery or previous damage to the study knee at any time, or minor knee surgery to the study knee within 1 year Requires oral or intra-muscular corticosteroids, or received an intra articular corticosteroid injection into the study knee within the past 90 days, or into any other joint within the past 30 days, or currently applying topical corticosteroids onto the study knee Received intra-articular viscosupplementation (eg, hylan G-F 20 [Synvisc®]) in the study knee in the past 6 months On prior stable therapy (ie, more than 3 days per week for the previous month) with an opioid analgesic prior to the screening visit will be excluded. Recently started taking a sedative hypnotic medication for insomnia Taking anti-depressants Not willing to discontinue prohibited medications/therapies Cannot tolerate acetaminophen Re-entering study after dropping out or withdrawn from study Used another investigational drug within the previous 30 days On or currently applying for disability benefits on the basis of knee OA History of fibromyalgia Other painful or disabling conditions affecting the knee or leg, or disabling condition of the hands (used to apply the study drug) Skin disorder with current involvement on the hands (used to apply the study drug) or the knee(s) (application site) Referred to an orthopedic surgeon for consideration of, or been advised to have, knee replacement or knee reconstruction surgery Radiologic evidence of OA of the knee advanced to the point that all cartilage has been eroded (ie, bone on bone) Recently started using a cane within the past 30 days History of chronic headaches that may require more than occasional use of rescue medication for headaches
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joseph Pierro, MD
Organizational Affiliation
Mallinckrodt
Official's Role
Study Director
Facility Information:
Facility Name
Genova Clinical Research
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85741
Country
United States
Facility Name
Benchmark Research
City
Sacramento
State/Province
California
ZIP/Postal Code
95816
Country
United States
Facility Name
Tampa Bay Medical Research, Inc
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33761
Country
United States
Facility Name
Avail Clinical Research
City
DeLand
State/Province
Florida
ZIP/Postal Code
32724
Country
United States
Facility Name
Comprehensive NeuroScience Inc.
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33716
Country
United States
Facility Name
Drug Studies America
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States
Facility Name
South Coast Medical Group
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31406
Country
United States
Facility Name
Clinical Trials Technology, Inc.
City
Prairie Village
State/Province
Kansas
ZIP/Postal Code
66206
Country
United States
Facility Name
Sterling Research
City
Erlanger
State/Province
Kentucky
ZIP/Postal Code
41018
Country
United States
Facility Name
Radiant Research Inc.
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
Facility Name
Sundance Clinical Research
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
Facility Name
Clinical Study Center of Asheville
City
Asheville
State/Province
North Carolina
ZIP/Postal Code
28803
Country
United States
Facility Name
Peters Medical Research, LLC
City
High Point
State/Province
North Carolina
ZIP/Postal Code
27262
Country
United States
Facility Name
Crescent Medical Research
City
Salisbury
State/Province
North Carolina
ZIP/Postal Code
28144
Country
United States
Facility Name
New Hanover Medical Research
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
Facility Name
Sterling Research
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45246
Country
United States
Facility Name
Radiant Research Inc.
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43212
Country
United States
Facility Name
Clinical Research Source, Inc.
City
Perrysburg
State/Province
Ohio
ZIP/Postal Code
43551
Country
United States
Facility Name
Radiant Research Inc.
City
Anderson
State/Province
South Carolina
ZIP/Postal Code
29261
Country
United States
Facility Name
Palmetto Medical Research
City
Mount Pleasant
State/Province
South Carolina
ZIP/Postal Code
29464
Country
United States
Facility Name
Holston Medical Group Clinical Research
City
Kingsport
State/Province
Tennessee
ZIP/Postal Code
37660
Country
United States
Facility Name
Benchmark Research
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76135
Country
United States
Facility Name
Benchmark Research
City
San Angelo
State/Province
Texas
ZIP/Postal Code
76904
Country
United States
Facility Name
Sun Research Institute
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78215
Country
United States
Facility Name
Charlottesville Medical Research
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22911
Country
United States
Facility Name
HypotheTest, LLC
City
Roanoke
State/Province
Virginia
ZIP/Postal Code
24018
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26506138
Citation
Wadsworth LT, Kent JD, Holt RJ. Efficacy and safety of diclofenac sodium 2% topical solution for osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled, 4 week study. Curr Med Res Opin. 2016;32(2):241-50. doi: 10.1185/03007995.2015.1113400. Epub 2015 Nov 17.
Results Reference
derived

Learn more about this trial

Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis

We'll reach out to this number within 24 hrs